nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT01365169,"""CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial""",Not Applicable,Recruiting,Interventional,Malignant Head and Neck Neoplasm; Malignant Neoplasm; Metastatic Malignant Neoplasm in the Neck; Metastatic Malignant Neoplasm in the Uterine Cervix; Pancreatic Adenocarcinoma; Pancreatic Neuroendocrine Carcinoma; Recurrent Colorectal Carcinoma; Stage I Colorectal Cancer AJCC v6 and v7; Stage I Hypopharyngeal Carcinoma AJCC v7; Stage I Major Salivary Gland Cancer AJCC v7; Stage I Nasopharyngeal Carcinoma AJCC v7; Stage I Oral Cavity Cancer AJCC v6 and v7; Stage I Oropharyngeal Carcinoma AJCC v6 and v7; Stage II Colorectal Cancer AJCC v7; Stage II Hypopharyngeal Carcinoma AJCC v6 and v7; Stage II Major Salivary Gland Cancer AJCC v7; Stage II Nasopharyngeal Carcinoma AJCC v7; Stage II Oral Cavity Cancer AJCC v6 and v7; Stage II Oropharyngeal Carcinoma AJCC v6 and v7; Stage IIA Colorectal Cancer AJCC v7; Stage IIB Colorectal Cancer AJCC v7; Stage IIC Colorectal Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage III Hypopharyngeal Carcinoma AJCC v7; Stage III Laryngeal Cancer AJCC v6 and v7; Stage III Major Salivary Gland Cancer AJCC v7; Stage III Nasopharyngeal Carcinoma AJCC v7; Stage III Oral Cavity Cancer AJCC v6 and v7; Stage III Oropharyngeal Carcinoma AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVA Hypopharyngeal Carcinoma AJCC v7; Stage IVA Laryngeal Cancer AJCC v7; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Nasopharyngeal Carcinoma AJCC v7; Stage IVA Oral Cavity Cancer AJCC v6 and v7; Stage IVA Oropharyngeal Carcinoma AJCC v7; Stage IVB Colorectal Cancer AJCC v7; Stage IVB Hypopharyngeal Carcinoma AJCC v7; Stage IVB Laryngeal Cancer AJCC v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Nasopharyngeal Carcinoma AJCC v7; Stage IVB Oral Cavity Cancer AJCC v6 and v7; Stage IVB Oropharyngeal Carcinoma AJCC v7; Metastatic or Locally Unresectable Solid Tumor,Exercise Intervention; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Health Telemonitoring; Quality-of-Life Assessment; Questionnaire Administration; Health Telemonitoring,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),590,2011-05-25,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT01365169
NCT02471170,Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases,,Enrolling by invitation,Observational,Pancreatic Diseases,,,Abramson Cancer Center at Penn Medicine,,100,2015-09-10,2035-01-01,United States,No,https://clinicaltrials.gov/study/NCT02471170
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT02843945,Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer,Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Cancer,Directional Brachytherapy Source Implant,,CivaTech Oncology,,80,2017-05-31,2028-10-30,United States,No,https://clinicaltrials.gov/study/NCT02843945
NCT03080974,Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,Phase 2,Recruiting,Interventional,Pancreatic Adenocarcinoma,Nivolumab; Irreversible Electroporation,,University of Louisville,,10,2017-08-14,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT03080974
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03608631,Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation,Phase 1/Phase 2,Recruiting,Interventional,KRAS NP_004976.2:p.G12D; Metastatic Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA,,M.D. Anderson Cancer Center,,28,2021-01-27,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03608631
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03745326,A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients,Phase 1/Phase 2,Recruiting,Interventional,Gastrointestinal Cancer; Pancreatic Cancer; Gastric Cancer; Colon Cancer; Rectal Cancer,Cyclophosphamide; Fludarabine; Aldesleukin; anti-KRAS G12D mTCR PBL,,National Cancer Institute (NCI),,70,2019-05-16,2028-12-01,United States,No,https://clinicaltrials.gov/study/NCT03745326
NCT03977233,Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer,Phase 2,Recruiting,Interventional,"Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable",Oxaliplatin; Leucovorin; Irinotecan Hydrochloride; 5-FU,,UNC Lineberger Comprehensive Cancer Center,,45,2019-06-12,2030-01-05,United States,No,https://clinicaltrials.gov/study/NCT03977233
NCT04005690,A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma,Early Phase 1,Recruiting,Interventional,Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma,Cobimetinib; Olaparib; Onvansertib; Azenosertib; Saruparib; Tremelimumab,,OHSU Knight Cancer Institute,"American Association for Cancer Research; Oregon Health and Science University; Genentech, Inc.; Cardiff Oncology",90,2019-08-01,2028-02-01,United States,No,https://clinicaltrials.gov/study/NCT04005690
NCT04119024,Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors,Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell Carcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Cyclophosphamide; Fludarabine Phosphate; Fludeoxyglucose F-18; IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Magnetic Resonance Imaging; Positron Emission Tomography,,Anusha Kalbasi,Parker Institute for Cancer Immunotherapy; Melanoma Research Alliance; California Institute for Regenerative Medicine (CIRM); City of Hope National Medical Center; Jonsson Comprehensive Cancer Center,18,2025-10-07,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04119024
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04291651,Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.,,Recruiting,Observational,Pancreatic Cyst; Pancreatic Neoplasms; Pancreatic Cancer; Pancreatic Diseases; Pancreatic Intraductal Papillary Mucinous Neoplasm; Intraductal Papillary Mucinous Neoplasm; Pancreatic Ductal Adenocarcinoma; Mucinous Cyst,Survey,,"University of California, San Francisco",,4000,2019-10-08,2030-01-01,United States,No,https://clinicaltrials.gov/study/NCT04291651
NCT04373564,Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group,Phase 4,Recruiting,Interventional,Motor Function; Cognitive Function; Contrast Media,Motor Tests; Cognitive Tests; Unenhanced-MRI of the brain; Gadolinium Measurements; Gadoxetate disodium; Gadobenate dimeglumine; Gadodiamide; Gadoterate meglumine; Gadobutrol; Gadoteridol,,Guerbet,Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor),2076,2021-03-24,2028-12-31,Brazil; Canada; France; Germany; Italy; Russia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04373564
NCT04421820,A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours,Phase 1/Phase 2,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma,BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion); BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation),,"Bold Therapeutics, Inc.",,220,2020-08-28,2026-09-01,Canada; Ireland; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04421820
NCT04484909,Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8,Hafnium Oxide-containing Nanoparticles NBTXR3; Radiation Therapy,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),24,2020-07-01,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04484909
NCT04588025,Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response,Not Applicable,Recruiting,Interventional,Pancreatic Cancer,"Point-of-care Portable Perfusion Phantom, P4",,University of Alabama at Birmingham,,55,2020-10-14,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04588025
NCT04609592,"Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery",Phase 1,Recruiting,Interventional,Gastroenteropancreatic Neuroendocrine Tumor,Lutathera; Gallium 68 Dotatate; Computed Tomography (CT); Magnetic Resonance Imaging (MRI); PET/CT,,Stanford University,Novartis Pharmaceuticals,10,2021-03-17,2027-09-05,United States,No,https://clinicaltrials.gov/study/NCT04609592
NCT04820179,"Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer",Phase 2,Recruiting,Interventional,Pancreatic Cancer; Metastatic Pancreatic Cancer,Cabozantinib + Atezolizumab,,University of Arizona,,29,2021-10-12,2026-01-31,United States,No,https://clinicaltrials.gov/study/NCT04820179
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT04989959,An Exploratory Study of [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma,Phase 1,Recruiting,Interventional,Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma,[18F]PT2385; Positron Emission Tomography/Computed Tomography; Biopsy,,Orhan Kemal Oz,,35,2021-08-18,2027-08-18,United States,No,https://clinicaltrials.gov/study/NCT04989959
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05018663,Artificial Intelligence for Rapid On-site Evaluation (AI-ROSE) for Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA) Biopsy of Pancreatic Solid Lesions: A Prospective Double Blinded Study,,Recruiting,Observational,Pancreatic Solid Lesions,Artificial Intelligence software ROSE,,"The University of Texas Health Science Center, Houston",,50,2021-07-21,2028-01-30,United States,No,https://clinicaltrials.gov/study/NCT05018663
NCT05053555,High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies,Not Applicable,Recruiting,Interventional,Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma,high dose rate brachytherapy; high dose rate brachytherapy,,M.D. Anderson Cancer Center,,60,2022-04-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05053555
NCT05053971,Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma,BET Bromodomain Inhibitor ZEN-3694; Computed Tomography; Core Biopsy; Entinostat,,National Cancer Institute (NCI),,49,2022-11-16,2026-07-01,United States,No,https://clinicaltrials.gov/study/NCT05053971
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05254171,"A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma",Phase 2/Phase 3,Recruiting,Interventional,Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV,SBP-101; Nab-paclitaxel; Gemcitabine; Placebo,,"Panbela Therapeutics, Inc.",,600,2022-08-08,2027-01-01,Australia; Austria; Belgium; France; Germany; Italy; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05254171
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05379985,A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS,Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-6236,,"Revolution Medicines, Inc.",,754,2022-05-31,2027-07-26,United States,No,https://clinicaltrials.gov/study/NCT05379985
NCT05382559,A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation,Phase 1,Recruiting,Interventional,Solid Tumor,ASP3082; Cetuximab; Leucovorin; Oxaplatin; Fluorouracil; Irinotecan; Nanoparticle albumin-bound-paclitaxel; Gemcitabine; Docetaxel; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed,,Astellas Pharma Inc,,651,2022-06-08,2026-10-31,China; France; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05382559
NCT05463796,"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer",,Recruiting,Observational,"Cancer Risk; Cancer Predisposition Syndrome; Hereditary Cancer Prediction; Childhood Cancer Survivors; Adult Cancer Survivors; IARC Carcinogens; Smoking History; Lung Cancer; Ductal/Lobular Carcinoma; Barrett Esophagus; Pancreatic Precursor Lesions; Colonic Dysplasia/Adenomata; Non-Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis; Cirrhosis; High Grade Prostatic Epithelial Neoplasia; High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ; Adenomatous Hyperplasia; High-risk Oral Precancerous Diseases; Melanocytic Lesion, Adult; Hematologic Malignancy; Lung; Node; Serous Tubal Intraepithelial Carcinoma; Endometrial Intraepithelial Neoplasia; Cervical and Endocervical Carcinoma in Situ; Vulvar Intraepithelial Neoplasia; Nephrogenic Rests; Benign Bone Lesions With Risk of Malignant Degeneration; Giant Cell Tumor; Osteochondroma; Spitz Nevus",Samples,,Dana-Farber Cancer Institute,,5000,2023-04-25,2032-03-25,United States,No,https://clinicaltrials.gov/study/NCT05463796
NCT05477576,"Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy",Phase 3,Recruiting,Interventional,GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET,RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide,,"RayzeBio, Inc.",,288,2022-03-24,2028-07-05,Belgium; Brazil; Canada; France; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05477576
NCT05685602,A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma,Phase 1,Recruiting,Interventional,Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Emavusertib; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Nab-paclitaxel; Positron Emission Tomography; X-Ray Imaging,,National Cancer Institute (NCI),,36,2023-06-12,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT05685602
NCT05687188,Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations,,Recruiting,Observational,Pancreatic Cancer,Blood Sample Collection; Tissue Sample Collection; Data Collection; Medical Image Collection,,H. Lee Moffitt Cancer Center and Research Institute,United States Department of Defense,125,2023-02-22,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05687188
NCT05732831,"A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Solid Tumor,TNG462; Pembrolizumab,,"Tango Therapeutics, Inc.",,225,2023-05-26,2026-09-05,France; Spain; United States,No,https://clinicaltrials.gov/study/NCT05732831
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05851924,Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma,Phase 2,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma,NALIRIFOX; AD-XRT and Capecitabine,,Memorial Sloan Kettering Cancer Center,Ipsen; Pancreatic Cancer Research Fund,60,2023-05-12,2026-05-05,United States,No,https://clinicaltrials.gov/study/NCT05851924
NCT05919238,A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Locally Advanced Unresectable Pancreatic Adenocarcinoma,Padeliporfin Vascular Targeted Photodynamic (VTP) therapy,,Impact Biotech Ltd,,30,2024-05-15,2026-10-30,United States,No,https://clinicaltrials.gov/study/NCT05919238
NCT05968326,"A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma",Phase 2,Recruiting,Interventional,"Adenocarcinoma, Pancreatic Ductal",Autogene cevumeran; Atezolizumab; mFOLFIRINOX,,"Genentech, Inc.",BioNTech SE,260,2023-10-18,2031-01-01,Belgium; Canada; France; Germany; Netherlands; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05968326
NCT05984602,A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer,Phase 1,Recruiting,Interventional,Pancreatic Cancer,Canakinumab; Tislelizumab; Nab-Paclitaxel; Gemcitabine,,NYU Langone Health,,10,2023-07-14,2026-01-01,United States,No,https://clinicaltrials.gov/study/NCT05984602
NCT05989724,"A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Breast Cancer; Pancreatic Cancer; Ovarian Cancer; Colorectal Cancer,SON-DP,,Qurgen Inc.,,150,2023-09-19,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT05989724
NCT06015659,Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination with Gemcitabine in Second-Line Advanced Pancreatic Adenocarcinoma,Phase 2,Recruiting,Interventional,Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma,Zentalis; Gemzar,,"Brandon Huffman, MD","Lustgarten Foundation; K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Stand Up To Cancer",34,2023-11-16,2027-06-01,United States,No,https://clinicaltrials.gov/study/NCT06015659
NCT06040541,"Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors,RMC-9805; RMC-6236,,"Revolution Medicines, Inc.",,604,2023-09-07,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT06040541
NCT06084481,A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications,Phase 1,Recruiting,Interventional,Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer,ABBV-400; Itraconazole (ITZ),,AbbVie,,285,2023-11-09,2026-07-05,Australia; Israel; Japan; Puerto Rico; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06084481
NCT06141031,Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma,Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Cancer,TTI-101,,"University of Colorado, Denver","Tvardi Therapeutics, Incorporated",18,2024-01-16,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT06141031
NCT06157671,"The LINFU® (A Noninvasive Method for Increasing Exfoliation of Pancreatic Ductal Cells Into Pancreatic Fluid) U.S. Registry for the Detection of Low and High- Grade Atypia and Early, Asymptomatic Pancreatic Ductal Adenocarcinoma (PDAC)",,Enrolling by invitation,Observational,Pancreatic Adenocarcinoma; Pancreatic Intraepithelial Neoplasia,,,"Adenocyte, LLC",,1000,2024-01-31,2030-06-01,United States,No,https://clinicaltrials.gov/study/NCT06157671
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06168812,Sulfonylurea Safety and Effectiveness (SUSS) for Patients With Hyperglycemia and Pancreatic Ductal Adenocarcinoma: A Pragmatic Clinical Trial and Accompanying Retrospective Revie,Phase 2,Recruiting,Interventional,Pancreatic Cancer; Pancreatic Carcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Metastatic; Metastatic Pancreatic Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,Glipizide,,Memorial Sloan Kettering Cancer Center,"University of California, Berkeley",40,2023-12-05,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06168812
NCT06179160,"A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumors,INCB161734; Cetuximab; Retifanlimab; GEMNabP; mFOLFIRINOX; FOLFOX; FOLFIRI; INCA33890,,Incyte Corporation,,710,2024-01-04,2027-01-01,Australia; Belgium; Canada; France; Italy; Japan; Spain; United States,No,https://clinicaltrials.gov/study/NCT06179160
NCT06218914,"Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,"Non-small Cell Lung Cancer; Colorectal Carcinoma; Pancreatic Ductal Adenocarcinoma; Endometrial Cancer; Solid Tumor, Adult; KRAS G12D","NT-112: Autologous, engineered T Cells targeting KRAS G12D; AZD0240: Autologous, engineered T Cells targeting KRAS G12D",,AstraZeneca,,24,2024-03-22,2043-11-18,United States,No,https://clinicaltrials.gov/study/NCT06218914
NCT06219941,"A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)",Phase 2,Recruiting,Interventional,Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma,AZD0901; 5-Fluorouracil; Leucovorin; l-leucovorin; Irinotecan; Nanoliposomal Irinotecan; Gemcitabine,,AstraZeneca,,190,2023-12-13,2026-12-31,Australia; Canada; China; Georgia; Japan; Malaysia; Moldova; Poland; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06219941
NCT06227377,"A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumors,QTX3034; Cetuximab,,Quanta Therapeutics,,250,2024-02-05,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT06227377
NCT06233877,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability, and Efficacy of Low Dose G-FLIP in Combination With Mitomycin C in Patients With Stage IV Pancreatic Cancer Who Have Failed First-Line Treatment",Phase 2,Not yet recruiting,Interventional,Pancreatic Cancer,G-GLIP plus Mitomycin C,,Hirschfeld Oncology,,60,2024-03-15,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT06233877
NCT06364696,An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation,Phase 1,Recruiting,Interventional,Solid Tumor,ASP4396,,Astellas Pharma Inc,,175,2024-04-16,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT06364696
NCT06385925,Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation,Phase 1/Phase 2,Recruiting,Interventional,Malignant Neoplasm,TSN1611; TSN1611; TSN1611; TSN1611,,Tyligand Pharmaceuticals (Suzhou) Limited,,440,2024-04-29,2027-04-30,China; United States,No,https://clinicaltrials.gov/study/NCT06385925
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06411691,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer,KRAS Vaccine with Poly-ICLC adjuvant; Balstilimab; Botensilimab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Agenus Inc.; Private Philanthropic Funds; National Cancer Institute (NCI); United States Department of Defense,54,2025-06-24,2029-07-01,United States,No,https://clinicaltrials.gov/study/NCT06411691
NCT06445062,A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma,RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805,,"Revolution Medicines, Inc.",,1130,2024-05-24,2027-07-15,United States,No,https://clinicaltrials.gov/study/NCT06445062
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06503146,18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection,Phase 2,Recruiting,Interventional,Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma; Pheochromocytoma/Paraganglioma (PPGL); Pancreatic Ductal Adenocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Gastric Cancer; Cholangiocarcinoma; Bladder Cancer,[18F]FAPI-74; [18F]FDG,,National Cancer Institute (NCI),,320,2025-09-09,2030-06-01,United States,No,https://clinicaltrials.gov/study/NCT06503146
NCT06539169,FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases,,Recruiting,Observational,Alpha-Thalassemia; Beta-Thalassemia; Amyloidosis; Amyotrophic Lateral Sclerosis; Creutzfeld-Jakob Disease; Cystic Fibrosis; Duchenne Muscular Dystrophy; Early-Onset Alzheimer Disease; Ehlers-Danlos Syndrome; Huntington Disease; Gaucher Disease; GM1 Gangliosidosis; Myasthenia Gravis; Pompe Disease; Sickle Cell Disease; Transthyretin Amyloid Cardiomyopathy; Rare Diseases,,,xCures,,1000,2024-06-10,2026-06-10,United States,No,https://clinicaltrials.gov/study/NCT06539169
NCT06582017,A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma,Phase 1,Recruiting,Interventional,Ovarian Cancer; Pancreas Cancer; Urothelial Carcinoma; Renal Cell Carcinoma; Hepatocellular Carcinoma; Gastrointestinal Cancer; Lung Cancer; Prostate Cancer; Breast Cancer,QXL138AM Injection every 2 weeks by IV Infusion,,Nammi Therapeutics Inc,,100,2024-08-28,2028-05-30,United States,No,https://clinicaltrials.gov/study/NCT06582017
NCT06586515,A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer,LY3962673; Cetuximab; Gemcitabine; nab-paclitaxel; Oxaliplatin; leucovorin; Irinotecan; 5-fluorouracil,,Eli Lilly and Company,,630,2024-09-12,2029-03-05,Canada; China; France; Germany; Ireland; Italy; Japan; Spain; United States,No,https://clinicaltrials.gov/study/NCT06586515
NCT06593431,Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial,Phase 3,Recruiting,Interventional,Pancreas Cancer; Oligometastatic,Consolidative Radiation,,M.D. Anderson Cancer Center,,80,2024-10-23,2029-06-29,United States,No,https://clinicaltrials.gov/study/NCT06593431
NCT06598007,"A Phase 1/2a First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients with Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma",CT3001,,"Crossignal Therapeutics, Inc.",,78,2024-09-20,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06598007
NCT06600906,Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer,,Recruiting,Observational,Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma,Hyperpolarized 13C-Pyruvate; Computed tomography (CT); Magnetic Resonance Imaging (MRI),,"University of California, San Francisco",National Cancer Institute (NCI),70,2024-10-01,2032-09-01,United States,No,https://clinicaltrials.gov/study/NCT06600906
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06619587,"A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumor,Phase I Arm A; Phase I Arm B,,"Genentech, Inc.",,410,2024-11-14,2028-05-31,Australia; Canada; Israel; Singapore; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06619587
NCT06648434,Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Phase 1,Recruiting,Interventional,Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Cancer of the Pancreas,Zunsemetinib; mFOLFIRINOX,,Washington University School of Medicine,"National Cancer Institute (NCI); Aclaris Therapeutics, Inc.",51,2025-05-15,2030-05-31,United States,No,https://clinicaltrials.gov/study/NCT06648434
NCT06651580,Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2),,Recruiting,Observational,Chronic Pancreatitis; Exocrine Pancreas Carcinoma; Recurrent Acute Pancreatitis,Biospecimen Collection; Quality-of-Life Assessment; Questionnaire Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),1600,2021-04-01,2027-02-02,Australia; Canada; Israel; United States,No,https://clinicaltrials.gov/study/NCT06651580
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06710756,"A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive",Phase 1/Phase 2,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Ovarian Cancer; Head and Neck Cancer; Sarcoma; Mesothelioma,[203Pb]Pb-PSV359; [212Pb]Pb-PSV359,,Perspective Therapeutics,,112,2025-04-28,2032-05-28,United States,No,https://clinicaltrials.gov/study/NCT06710756
NCT06712797,Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center (PANTHER-PIC),Not Applicable,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Intraductal Papillary Mucinous Neoplasm,Physical Activity (PA); Nutrition (N),,H. Lee Moffitt Cancer Center and Research Institute,Miles for Moffitt,24,2025-02-19,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT06712797
NCT06790602,"A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.",Phase 2,Not yet recruiting,Interventional,Pancreatic Ductal Adenocarcinoma (mPDAC),Cemiplimab Plus Gemcitabine,,"University of California, San Diego",Regeneron Pharmaceuticals,43,2025-11-05,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT06790602
NCT06797336,"A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor,PT0253,,"PAQ Therapeutics, Inc.",,115,2024-12-19,2027-06-16,United States,No,https://clinicaltrials.gov/study/NCT06797336
NCT06807437,A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula,Phase 3,Recruiting,Interventional,Pancreatic Carcinoma; Pancreatic Neoplasm,Biospecimen Collection; Distal Pancreatectomy; Lanreotide; Questionnaire Administration; Saline,,SWOG Cancer Research Network,National Cancer Institute (NCI),274,2025-05-09,2027-11-01,United States,No,https://clinicaltrials.gov/study/NCT06807437
NCT06821997,A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study),Phase 2,Recruiting,Interventional,Borderline Resectable Pancreatic Ductal Adenocarcinoma,Biospecimen Collection; Computed Tomography; Fluorouracil; Irinotecan Sucrosofate; Leucovorin Calcium; Oxaliplatin; Surgical Procedure,,Roswell Park Cancer Institute,,20,2025-12-01,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT06821997
NCT06843551,"A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami ""EMPIRE"" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation",Phase 2,Recruiting,Interventional,Metastatic Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer,Stereotactic Body Radiation Therapy; Botensilimab; Balstilimab,,Benjamin Spieler,Agenus Inc.,20,2025-06-18,2030-08-01,United States,No,https://clinicaltrials.gov/study/NCT06843551
NCT06850623,A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer,Phase 2,Recruiting,Interventional,Locally Advanced Pancreatic Adenocarcinoma,Acoustic Cluster Therapy; Modified FOLFIRINOX,,EXACT Therapeutics AS,,25,2025-06-19,2027-07-15,United States,No,https://clinicaltrials.gov/study/NCT06850623
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06937996,Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System,,Recruiting,Observational,Pancreatic Cancer Non-resectable,NanoKnife,,Englewood Hospital and Medical Center,,25,2025-05-13,2035-05-31,United States,No,https://clinicaltrials.gov/study/NCT06937996
NCT06941857,"A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer",Phase 2,Recruiting,Interventional,Pancreatic Cancer,Oxaliplatin; Irinotecan; Folinic Acid; 5-Fluorouracil (5-FU); NC410; Nivolumab; Ipilimumab,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,"NextCure, Inc.; Lustgarten Foundation",20,2025-09-04,2030-09-05,United States,No,https://clinicaltrials.gov/study/NCT06941857
NCT06984562,Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study,Not Applicable,Recruiting,Interventional,Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA),Adaptive Radiation Therapy,,Fox Chase Cancer Center,,16,2025-08-20,2029-08-01,United States,No,https://clinicaltrials.gov/study/NCT06984562
NCT07020221,"A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS",VS-7375; Cetuximab; Carboplatin + Pemetrexed + Pembrolizumab; Gemcitabine; Gemcitabine + Nab-paclitaxel,,"Verastem, Inc.",,330,2025-06-24,2028-09-05,United States,No,https://clinicaltrials.gov/study/NCT07020221
NCT07021066,"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Gastric Adenocarcinoma; Advanced Pancreatic Ductal Adenocarcinoma; Esophageal Adenocarcinoma; Biliary Tract Cancer; Other Solid Tumors,BL-M05D1,,SystImmune Inc.,,120,2025-07-30,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT07021066
NCT07023731,"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,KRAS G12D Mutation; Advanced Solid Cancer,ARV-806,,Arvinas Inc.,,159,2025-05-29,2029-04-02,United States,No,https://clinicaltrials.gov/study/NCT07023731
NCT07033689,"Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients",Early Phase 1,Not yet recruiting,Interventional,Pancreatic Cancer,Suizenji (an ultrasound-guided HIFU therapy system); Nal-IRI/FL; mFOLFIRINOX adjuvant chemotherapy; Gem/nab-PTX,,SONIRE Therapeutics Inc.,,10,2025-12-01,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT07033689
NCT07043270,24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial,Phase 2,Recruiting,Interventional,Pancreas Adenocarcinoma,Nab-paclitaxel + Gemcitabine; modified FOLFIRINOX (mFOLFIRINOX),,Dartmouth-Hitchcock Medical Center,,35,2025-09-29,2029-07-01,United States,No,https://clinicaltrials.gov/study/NCT07043270
NCT07094204,A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications,Phase 1,Recruiting,Interventional,Solid Tumor; Non-Small-Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer,ASP5834; panitumumab,,Astellas Pharma Inc,,364,2025-07-25,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT07094204
NCT07118176,PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients,Phase 1,Recruiting,Interventional,Anal Carcinoma; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Head and Neck Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Hepatocellular Carcinoma; Lung Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Neoplasm of Unknown Primary; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Uterine Neoplasm; Neuroendocrine Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Penile Carcinoma; Pleural Carcinomatosis; Primary Peritoneal Carcinoma; Prostate Carcinoma; Salivary Gland Carcinoma; Sarcoma; Skin Carcinoma; Solitary Fibrous Tumor; Thymus Carcinoma; Thyroid Gland Carcinoma; Thyroid Gland Medullary Carcinoma; Urothelial Carcinoma; Vaginal Carcinoma,Computed Tomography; Fludeoxyglucose F-18; Gallium Ga 68 FAPi-46; Positron Emission Tomography,,Jonsson Comprehensive Cancer Center,,30,2025-08-01,2027-09-07,United States,No,https://clinicaltrials.gov/study/NCT07118176
NCT07174609,A Pilot Study of Scrambler Therapy for Painful Chronic Pancreatitis,Not Applicable,Recruiting,Interventional,Chronic Pain; Pancreatitis; Chronic Pancreatitis,Scrambler Therapy,,Johns Hopkins University,The National Pancreas Foundation,40,2024-11-01,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT07174609
NCT07186842,"First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Cancers,BNT329; CA19-9-targeting monoclonal antibody,,BioNTech SE,,245,2025-11-18,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT07186842
NCT07207707,"A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation",Phase 1,Recruiting,Interventional,Solid Tumor Malignancies,KQB548,,Kumquat Biosciences Inc.,,78,2025-09-16,2027-03-05,United States,No,https://clinicaltrials.gov/study/NCT07207707
NCT07213791,"A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)",Phase 1,Recruiting,Interventional,Ovarian Neoplasms; Breast Neoplasms; Pancreatic Intraductal Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Cholangiocarcinoma,LY4337713,,Eli Lilly and Company,,241,2025-10-22,2033-03-05,Netherlands; United States,No,https://clinicaltrials.gov/study/NCT07213791
NCT07214298,A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma,Phase 1/Phase 2,Not yet recruiting,Interventional,Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Fluorouracil; Irinotecan; Leucovorin Calcium; Magnetic Resonance Imaging; Oxaliplatin; Pegcetacoplan,,Roswell Park Cancer Institute,,35,2025-12-01,2028-10-01,United States,No,https://clinicaltrials.gov/study/NCT07214298
NCT07217717,"A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults With Pancreatic Ductal Adenocarcinoma",Phase 3,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma (PDAC),[18F]FAPI-74 PET/CT,,SOFIE,,200,2025-12-11,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT07217717
NCT07223047,"A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC),BMS-986523; Gemcitabine; Nab-Paclitaxel; Cetuximab; Pembrolizumab,,Bristol-Myers Squibb,,252,2025-11-25,2028-10-13,Canada; Spain; United States,No,https://clinicaltrials.gov/study/NCT07223047
NCT07224750,A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer,,Recruiting,Observational,Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Esophageal Squamous Cell Carcinoma (ESCC); Gastric Cancer (GC); Colorectal Cancer Screening,,,City of Hope Medical Center,,1000,2024-06-21,2026-06-18,United States,No,https://clinicaltrials.gov/study/NCT07224750
